Form 4 for VCYT VERACYTE, INC.
Accepted 2025-03-06 00:00:00 ET · period of report 2025-03-04 · accession 0001384101-25-000032 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-03-06 | 2025-03-04 | VCYT | Febbo Phillip G. | Chief Scientific, Med Off | S - Sale | $33.34 | -8,037 | 82.5K | -9% | -$268.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-04 | S | D | 4,467 | $32.86 | 86,110 | D | — | — | (F2) Represents weighted average sales price. Sale prices for the transactions range from $32.50 to $33.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |
| 2 | Common | Common Stock | 2025-03-04 | S | D | 3,570 | $33.95 | 82,540 | D | — | — | (F3) Represents weighted average sales price. Sale prices for the transactions range from $33.56 to $34.42. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |